ANIKA THERAPEUTICS ($ANIK) posted quarterly earnings results for Q4 2025 on Thursday, February 26th. The company reported earnings of $0.31 per share, beating estimates of -$0.22 by $0.53. The company also reported revenue of $30,620,000, beating estimates of $29,452,500 by $1,167,500.
You can see Quiver Quantitative's $ANIK stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
ANIKA THERAPEUTICS Hedge Fund Activity
We have seen 75 institutional investors add shares of ANIKA THERAPEUTICS stock to their portfolio, and 56 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- TRIGRAN INVESTMENTS, INC. removed 1,452,815 shares (-89.6%) from their portfolio in Q4 2025, for an estimated $13,961,552
- OPALEYE MANAGEMENT INC. removed 588,797 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $5,534,691
- ALTA FUNDAMENTAL ADVISERS LLC removed 454,944 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $4,276,473
- MORGAN STANLEY added 377,489 shares (+95.6%) to their portfolio in Q4 2025, for an estimated $3,627,669
- STONEPINE CAPITAL MANAGEMENT, LLC removed 190,590 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $1,791,546
- TWO SIGMA INVESTMENTS, LP added 153,887 shares (+192.5%) to their portfolio in Q4 2025, for an estimated $1,478,854
- D. E. SHAW & CO., INC. added 122,664 shares (+70.0%) to their portfolio in Q4 2025, for an estimated $1,178,801
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
ANIKA THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $ANIK in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Barrington Research issued a "Outperform" rating on 11/06/2025
To track analyst ratings and price targets for ANIKA THERAPEUTICS, check out Quiver Quantitative's $ANIK forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
